Profusa Signs Option to Acquire G3 Vision Labs Contingent on $30M Financing

Key Facts

In a move reflecting its expansion strategy within the medical diagnostics sector, Profusa has entered into an option agreement to acquire 100% of G3 Vision Labs and its affiliates. According to reports, the target assets include Med Screen Laboratories, Dominion Diagnostics, and Acutis Diagnostics. However, the completion of the acquisition is strictly contingent on securing at least $30 million in new financing and obtaining necessary stockholder approvals.

The deal comes at a time when the company faces operational and regulatory hurdles, as exercising the acquisition option requires meeting rigorous conditions, including debt consents or repayment at the target entities. Under the agreement signed on July 31, 2026, sellers received common and preferred shares in Profusa as initial consideration. Maintaining the company's Nasdaq listing remains a critical requirement for the transaction, placing additional pressure on management to secure the required capital.

Technically, updated price data for the instrument was unavailable at the close of August 1, 2026, making the qualitative direction of the stock dependent on the company's success in raising the $30 million. Traders are closely monitoring the firm's ability to meet listing requirements in the coming period. On the macroeconomic front, recent data showed the Federal Reserve held interest rates at 3.75% on July 29, 2026, which may influence the company's future financing costs.